The American Cancer Society states that ovarian cancer is the fifth leading cause of cancer-related death in women in the United States. The organization also says that, in 2022, nearly 13,000 people...
According to the CDC, of all people with diabetes, up to 10% have type 1 diabetes (T1D), sometimes referred to as juvenile or insulin-dependent diabetes. This type of diabetes typically develops early...
AstraZeneca and Avillion recently teamed up to develop PT027, an asthma rescue inhaler. PT027 is a pressurized metered-dose inhaler that delivers a fixed dose of two combined asthma medications,...
BMC Psychiatry states that up to one-third of patients with major depressive disorder become resistant to treatment, otherwise known as treatment-resistant depression. In recent years, psilocybin and...
According to an announcement by the NHS, the first humans have been transfused with lab-grown red blood cells as part of the RESTORE trial. The RESTORE trial is a randomized clinical trial in which red...
On October 18, 2022, the United States Department of Health and Human Services (HHS) announced its plans to allocate new funding to combat the mental health crisis. Under the guidance of the Biden administration and the Bipartisan Safer...
On October 21, 2022, JAMA Network Open published the results of a randomized clinical trial on the effects of emergency room motivational interventions on substance use disorders (SUD). Using a cohort...
According to the WHO, major depressive disorder (MDD) is the most common illness, affecting approximately 280 million people worldwide. That said, treating depression presents a unique challenge for providers. With several medications...
According to a press statement released on October 18, 2022, the Treventis Corporation, a biotechnology company, was granted $2.97 million to research and develop an anti-tau misfolding drug. The press...
Milestone Pharmaceuticals recently announced positive test results from a phase III clinical trial of etripamil, a calcium channel blocker to treat paroxysmal supraventricular tachycardia (PSVT). PSVT...
On October 11, 2022, GT Medical announced the first participant enrolled in the GammaTile Enhanced Stupp ALTernative (GESTALT) trial. While this trial is still in its infancy, if the results are favorable, it may influence protocols for...
Months after announcing the development of a nasal epinephrine rescue medication, Orexo Pharmaceuticals announced positive phase I clinical trial data on the drug — called OX640. Epinephrine is a...
Using data from ClinicalTrials.gov, researchers collected data on eligibility criteria from approximately 100 clinical research protocols. Of the 97 interventional studies, 14 focused on dementia, 24...
Opioid use disorder (OUD) has become a very prevalent substance abuse issue. According to the CDC, approximately 75% of overdoses in 2022 involved an opioid in the United States. The pharmaceutical industry has contributed significantly to...
Today, Walmart joined many other companies to improve clinical research for marginalized communities by launching its clinical research mission. The Walmart Healthcare Research Institute (WHRI) will be...
For many minority communities, marijuana possession and use can lead to years of incarceration for nonviolent offenses. The Biden administration has recognized that the harsh punishment around...
On November 13, 2017, Abilify MyCite became the first digital pill approved by the United States FDA. Since this approval and the initial surge of digital pills — sometimes called smart pills — the uptake and utilization have...
Between 2016 and 2022, the AMA surveyed approximately 1,300 providers in the United States for AMA Digital Health Research. This data collected information on motivations and requirements for digital...
Throughout the COVID-19 pandemic, researchers and clinicians have worked tirelessly to develop new antiviral therapies to prevent, treat, and minimize the effects of the SARS-CoV-2 viral infection....
Results from the Phase III CodeBreaK 200 clinical trial found that Amgen’s targeted therapy Lumakras successfully extended progression-free survival (PFS) by about two months and was 15% more...
